Testosterone regulation of homocysteine metabolism modulates redox status in human prostate cancer cells.

Clearance of homocysteine via the transsulfuration pathway provides an endogenous route for cysteine synthesis and represents a quantitatively significant source of this amino acid needed for glutathione synthesis. Men have higher plasma levels of total homocysteine than do women, but the mechanism of this sex-dependent difference is not known. In this study, we investigated regulation by testosterone of cystathionine beta-synthase (CBS), which catalyzes the committing step in the transsulfuration pathway. We report that testosterone downregulates CBS expression via a posttranscriptional mechanism in the androgen-responsive prostate cancer cell line, LNCaP. This diminution in CBS levels is accompanied by a decrease in flux through the transsulfuration pathway and by a lower intracellular glutathione concentration. The lower antioxidant capacity in testosterone-treated prostate cancer cells increases their susceptibility to oxidative stress conditions. These results demonstrate regulation of the homocysteine-clearing enzyme, CBS, by testosterone and suggest the potential utility of targeting this enzyme as a chemotherapeutic strategy.

[1]  B. Wilson,et al.  Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy. , 2007, Neoplasia.

[2]  T. Finkel.  Oxidant signals and oxidative stress. , 2003, Current opinion in cell biology.

[3]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[4]  S. Batra,et al.  Establishment and characterization of androgen‐independent human prostate cancer LNCaP cell model , 2002, The Prostate.

[5]  B. Ames.  Mutagenesis and carcinogenesis: Endogenous and exogenous factors , 1989, Environmental and molecular mutagenesis.

[6]  G. Wilding.  Endocrine control of prostate cancer. , 1995, Cancer surveys.

[7]  T. Visakorpi,et al.  Molecular Biology of Progression of Prostate Cancer , 1999, European Urology.

[8]  Fazoil I Ataullakhanov,et al.  Analysis of pathological defects in methionine metabolism using a simple mathematical model. , 2005, Biochimica et biophysica acta.

[9]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[10]  Joanne I. Yeh,et al.  Protein-sulfenic acids: diverse roles for an unlikely player in enzyme catalysis and redox regulation. , 1999, Biochemistry.

[11]  P. Cerutti.  Prooxidant states and tumor promotion. , 1985, Science.

[12]  D. Peehl,et al.  Tumor‐selective killing by selenite in patient‐matched pairs of normal and malignant prostate cells , 2006, The Prostate.

[13]  B. Ames,et al.  The free radical theory of aging matures. , 1998, Physiological reviews.

[14]  E. Small,et al.  Prostate cancer update: 2006 , 2007, Current opinion in oncology.

[15]  L. Eaves,et al.  cDNA microarray analysis identifies genes induced in common by peptide growth factors and androgen in human prostate epithelial cells , 2005, Molecular carcinogenesis.

[16]  W C Willett,et al.  The causes and prevention of cancer. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Kurahashi,et al.  Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease. , 2005, Journal of the American Society of Nephrology.

[18]  A. Belldegrun,et al.  Effect of L‐buthionine sulfoximine on the radiation response of human renal carcinoma cell lines , 1993, Cancer.

[19]  J. Pounds,et al.  Arsenite disrupts mitosis and induces apoptosis in SV40-transformed human skin fibroblasts. , 2002, Toxicology and applied pharmacology.

[20]  Shelly C. Lu,et al.  S-adenosylmethionine stabilizes cystathionine beta-synthase and modulates redox capacity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Y. Pu,et al.  Resistance to paclitaxel is proportional to cellular total antioxidant capacity. , 2005, Cancer research.

[22]  E. Mosharov,et al.  The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. , 2000, Biochemistry.

[23]  J. Taub,et al.  Transcriptional Regulation of Cell-specific Expression of the Human Cystathionine β-Synthase Gene by Differential Binding of Sp1/Sp3 to the −1b Promoter* , 2001, The Journal of Biological Chemistry.

[24]  G. Lenaz.  Role of mitochondria in oxidative stress and ageing. , 1998, Biochimica et biophysica acta.

[25]  A. Isaksson,et al.  Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status , 1992, European journal of clinical investigation.

[26]  R. Banerjee,et al.  Testosterone regulation of renal cystathionine beta-synthase: implications for sex-dependent differences in plasma homocysteine levels. , 2007, American journal of physiology. Renal physiology.

[27]  G. Wilding,et al.  Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. , 1997, Journal of the National Cancer Institute.

[28]  S. Skaper,et al.  An automated colorimetric microassay for neuronotrophic factors. , 1986, Brain research.

[29]  D. Peehl,et al.  Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. , 2005, Free radical biology & medicine.

[30]  R. Dargel.  Lipid peroxidation--a common pathogenetic mechanism? , 1992, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[31]  G. Bounous,et al.  Molecular pathogenesis and prevention of prostate cancer. , 2004, Anticancer research.

[32]  J. Taub,et al.  Transcriptional regulation of the human cystathionine beta-synthase -1b basal promoter: synergistic transactivation by transcription factors NF-Y and Sp1/Sp3. , 2001, The Biochemical journal.

[33]  A. Schönthal,et al.  Expression of Human Prostatic Acid Phosphatase Correlates with Androgen-stimulated Cell Proliferation in Prostate Cancer Cell Lines* , 1998, The Journal of Biological Chemistry.

[34]  B. Chatterjee.  The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer , 2003, Molecular and Cellular Biochemistry.

[35]  K. Kitchin.  Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. , 2001, Toxicology and applied pharmacology.

[36]  B. Ames,et al.  Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. , 1983, Science.

[37]  G A Colditz,et al.  Intake of carotenoids and retinol in relation to risk of prostate cancer. , 1995, Journal of the National Cancer Institute.

[38]  J. Selhub,et al.  Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits. , 1996, The American journal of clinical nutrition.

[39]  O. Ogawa,et al.  Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine , 2004, Cell Death and Differentiation.

[40]  W. Gerald,et al.  The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. , 2005, Molecular endocrinology.

[41]  A. Bäumer,et al.  Down-regulation of Intrinsic P-glycoprotein Expression in Multicellular Prostate Tumor Spheroids by Reactive Oxygen Species* , 2001, The Journal of Biological Chemistry.

[42]  R. Banerjee,et al.  Expression profiling of homocysteine junction enzymes in the NCI60 panel of human cancer cell lines. , 2005, Cancer research.

[43]  A. Vercesi,et al.  Mitochondrial damage induced by conditions of oxidative stress. , 1999, Free radical biology & medicine.